In Vivo and in Vitro Suppression of T-Cell Receptor β/β CD4-CD8- T Lymphocytes by Cyclosporine A

Edward G. Brooks, Daniel P. Wirt, Gary R. Klimpel, Smita Vaidya, Randall M. Goldblum

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

We treated a patient with a combined immunodeficiency and disease pathology resembling GvHD with cyclosporine. This disorder was characterized by exfoliative dermatitis, lymphadenopathy, and lymphocytosis of a novel T-cell phenotype (CD3+ TCR β/β+ CD4- CD8-). The patient’s peripheral blood T cells had elevated cytolytic activity and expressed increased levels of IL2R, HLA-DR, and CD45RO. Treatment with CsA resulted in marked clinical improvement, resolution of the lymphocytosis, and reduced cytolytic activity of peripheral blood T cells. T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR β/β+ CD4- CD8- cell lines. Our data suggest that alleviation of the patient's clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR β/β+ CD4- CD8- T lymphocytes in vivo. The response of this patient to cyclosporine, which was similar to that seen in true GvHD, provides further evidence that these conditions share common pathogenetic pathways.

Original languageEnglish (US)
Pages (from-to)224-231
Number of pages8
JournalClinical Immunology and Immunopathology
Volume67
Issue number3
DOIs
StatePublished - Jun 1993

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology

Fingerprint Dive into the research topics of 'In Vivo and in Vitro Suppression of T-Cell Receptor β/β CD4<sup>-</sup>CD8<sup>-</sup> T Lymphocytes by Cyclosporine A'. Together they form a unique fingerprint.

  • Cite this